Search Medical Condition
Please enter condition
Please choose location from dropdown

Olsztyn, Poland Clinical Trials

A listing of Olsztyn, Poland clinical trials actively recruiting patients volunteers.

RESULTS

Found (52) clinical trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042 an Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion. The cohort expansion may include various tumor ...

Phase

0.0 miles

Learn More »

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients

Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated with homologous recombination (HR) DNA repair deficiency (HRD). The safety and efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. An oral ...

Phase

0.0 miles

Learn More »

Dose Optimization Study of Idelalisib in Follicular Lymphoma

This study will optimize the safety and efficacy of chronic administration of idelalisib in participants with follicular lymphoma (FL) and evaluate the overall safety profile of idelalisib and the overall response rate (ORR) by Week 24.

Phase

0.0 miles

Learn More »

A Multinational Randomized Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

The primary objective of the study is to compare overall survival of patients randomized to receiving custirsen in combination with docetaxel (Arm A) with patients randomized to receive docetaxel alone (Arm B).

Phase

0.0 miles

Learn More »

Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis.

Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS)

Phase

0.0 miles

Learn More »

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in ...

Phase

0.0 miles

Learn More »

Study of the Efficacy Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Phase

0.0 miles

Learn More »

A PK Study of Melphalan During Treatment With Melflufen and Dex in RRMM Pat With Impaired Renal Function

This is a multicenter, PK study of Melphalan during treatment with Melflufen and Dexamethasone in patients with RRMM and impaired renal function. Received 1 - 4 prior lines of therapy and a renal function (creatinine clearance by Cockcroft-Gault formula) between 30 mL/min to <45 mL/min.

Phase

0.0 miles

Learn More »

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).

Phase

0.0 miles

Learn More »

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ) Compared to Placebo and Adalimumab in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

The goal of this Phase III study is to assess the safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who have responded inadequately to MTX. The primary endpoint of the trial is at Week 12. Olokizumab is expected to reduce the disease activity and ...

Phase

0.05 miles

Learn More »